Financials in USD. Standardized financial statements.
A compact view of how Eagle Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $316.61M | $171.55M | $187.80M | $195.89M | $213.31M | $236.71M | $189.48M | $66.23M | $19.10M | $13.68M |
| Revenue Growth? | +84.6% | -8.7% | -4.1% | -8.2% | -9.9% | +24.9% | +186.1% | +246.8% | +39.6% | 0.0% |
| Cost of Revenue? | $94.94M | $42.18M | $45.47M | $60.90M | $61.92M | $57.19M | $55.31M | $15.65M | $11.71M | $7.38M |
| Gross Profit? | $221.67M | $129.37M | $142.34M | $135.00M | $151.40M | $179.52M | $134.18M | $50.58M | $7.38M | $6.30M |
| Gross Margin? | +70.0% | +75.4% | +75.8% | +68.9% | +71.0% | +75.8% | +70.8% | +76.4% | +38.7% | +46.0% |
| Operating Expenses? | $140.71M | $126.60M | $109.38M | $113.18M | $104.93M | $104.02M | $82.58M | $48.02M | $26.14M | $14.75M |
| Operating Income? | $80.96M | $2.77M | $32.95M | $21.82M | $36.62M | $73.99M | $53.35M | $2.56M | -$18.76M | -$8.46M |
| EBITDA? | $77.50M | $847,000 | $30.02M | $29.34M | $40.44M | $77.83M | $55.02M | $2.70M | -$18.76M | -$8.41M |
| Income Before Tax | $61.43M | -$4.55M | $22.68M | $22.00M | $34.04M | $72.94M | $53.43M | $2.57M | -$19.27M | -$6.95M |
| Income Tax Expense | $25.79M | $4.08M | $10.69M | $7.68M | $2.13M | $21.00M | -$28.03M | $3,000 | -$1.29M | -$898,703 |
| Net Income? | $35.64M | -$8.63M | $11.99M | $14.31M | $31.90M | $51.94M | $81.45M | $2.57M | -$17.98M | -$6.05M |
| EPS? | $2.76 | $-0.66 | $0.89 | $1.04 | $2.16 | $3.44 | $5.24 | $0.17 | $-1.81 | $-0.57 |
| Diluted EPS? | $2.73 | $-0.66 | $0.87 | $1.01 | $2.09 | $3.27 | $4.96 | $0.16 | $-1.81 | $-0.57 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality